Lung Cancer
August 2017 Vol 8, No 8 | August 3, 2017
In the longest follow-up on single-agent nivolumab to date, 5-year overall survival (OS) was 16% in patients with advanced non–small cell lung cancer (NSCLC) in updated results from a phase 1b dose-ranging study (CA209-003).
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
As Dr Mita reported at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, plinabulin is a small molecule with tumor-inhibiting and immune-enhancing effects.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
Durability of benefit—the possibility for sustained remission in patients with previously incurable disease—is already one of the hallmarks of immunotherapy. According to recent statistical analysis, however, this durability may even exceed expectations.
March 2017 Vol 8, No 3 | March 7, 2017
Around 80% of lung cancer patients experience some level of psychological distress, but regardless of the availability of psychosocial services, nurses can employ simple interventions to reduce the psychological distress of patients and improve their quality of life, according to Andreja C. Skufca-Smrdel, MSc, a clinical psychologist and psychotherapist in the Department of Psycho-oncology at the Institute of Oncology in Ljubljana, Slovenia.
February 2017 Vol 8, No 2 | February 13, 2017
Lung cancer patients experience considerable physical and psychosocial sequelae of their treatment in addition to preexisting comorbidities, but there are many opportunities to intervene through surveillance, screening, and management delivered as part of a survivorship program, according to James Huang, MD, a thoracic surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY.
November 2016 Vol 7, No 10 | November 2, 2016
Racial inequality in healthcare is a long-standing problem that has been studied for decades.
October 2016 Vol 7, No 9 | September 23, 2016
A positive impact is seen in the timeliness to treatment for cancer patients presented at a thoracic multidisciplinary conference.
Tammy Baxter, MD, Brook Blackmore, MSN, RN, Howard A. Burris, MD, Melissa L. Johnson, MD, Sharon Moore, RN, Priscilla Smith, RN, David R. Spigel, MD
October 2016 Vol 7, No 9 | September 23, 2016
This work indicates that the use of technology can improve diagnosis of early-stage lung cancer in the ER setting within the general population.
October 2016 Vol 7, No 9 | September 23, 2016
Previous studies have suggested that guideline-recommended therapy improves survival and reduces cost among patients with metastatic non–small cell lung cancer (mNSCLC). The purpose of this study was to explore the relationship between guideline-recommended initiation of therapy (GRI) in patients with mNSCLC and patient-reported outcomes (PROs), such as health-related quality of life (HRQOL) and patient-reported cancer symptoms.
Nora J. Barrett, BSN, RN, OCN, ONN-CG, Kristi L. Case, MS, CHES, CHW, Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG
June 2016 Vol 7, No 5 | June 7, 2016
The authors present their report on decreasing the time between the physician’s order for LDCT and date of actual screening.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512